Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRENE.L Regulatory News (RENE)

  • There is currently no data for RENE

Director/PDMR Shareholding

16 Sep 2005 13:06

ReNeuron Group plc16 September 2005 NOTIFICATION OF TRANSACTIONS OF DIRECTORS/PERSONS DISCHARGINGMANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1). (1) An issuer making a notification in respect of a transactionrelating to the shares or debentures of the issuer should complete boxes 1 to16, 23 and 24. (2) An issuer making a notification in respect of a derivative relatingto the shares of the issuer should complete boxes 1 to 4, 6, 8,13, 14, 16, 23and 24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24. (4) An issuer making a notification in respect of a financialinstrument relating to the shares of the issuer (other than a debenture) shouldcomplete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or RENEURON GROUP PLC (ii) DR3.1.4(R)(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) (ii) 3. Name of person discharging managerial 4. State whether notification relates to a person responsibilities/director connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person JOHN SINDEN MICHAEL HUNT 5. Indicate whether the notification is in 6. Description of shares (including class), respect of a holding of the person referred debentures or derivatives or financial to in 3 or 4 above or in respect of a instruments relating to shares non-beneficial interest3 7. Name of registered shareholders(s) and, if 8. State the nature of the transaction more than one, the number of shares held by each of them 9. Number of shares, debentures or financial 10. Percentage of issued class acquired (treasury instruments relating to shares acquired shares of that class should not be taken into account when calculating percentage) 11. Number of shares, debentures or financial 12. Percentage of issued class disposed (treasury instruments relating to shares disposed shares of that class should not be taken into account when calculating percentage) 13. Price per share or value of transaction 14. Date and place of transaction 15. Total holding following notification and 16. Date issuer informed of transaction total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised ANY TIME DURING THE PERIOD ENDING 23 JULY 2014 6 SEPTEMBER 2005 19. Total amount paid (if any) for grant of the 20. Description of shares or debentures involved option (class and number) JOHN SINDEN 650,000 ORDINARY SHARES NIL MICHAEL HUNT 900,000 ORDINARY SHARES 21. Exercise price (if fixed at time of grant) 22. Total number of shares or debentures over or indication that price is to be fixed at the time which options held following notification of exercise £0.10 PER SHARE JOHN SINDEN 1,955,260 OPTIONS AND WARRANTS MICHAEL HUNT 1,929,500 OPTIONS AND WARRANTS 23. Any additional information 24. Name of contact and telephone number for queries TIM MICKLEY, COLLINS STEWART 020 7523 8000 REPLACEMENT OPTIONS GRANTED UNDER THE COMPANY'S NEW SHARE OPTION SCHEME MICHAEL HUNT RENEURON 01483 302 560 Name and signature of duly authorised officer of issuer responsible for making notification MICHAEL HUNT CHIEF EXECUTIVE OFFICER-______________________________________ Date of notification 16/9/05 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Oct 201010:26 amRNS18th Annual BioPartnering Europe conference
8th Sep 201011:07 amRNSResults of 2010 Annual General Meeting
8th Sep 20107:00 amRNS2010 AGM Trading Update
9th Aug 20107:00 amRNSPosting of Report and Accounts and AGM date
3rd Aug 20107:00 amRNSDirector/PDMR Shareholding
15th Jul 20107:00 amRNSNotification of Investor Evening
12th Jul 20107:00 amRNSResult of pre-clinical studies
29th Jun 20107:00 amRNSPreliminary Results
17th Jun 20107:00 amRNSPreliminary Results Notification
13th May 20102:38 pmRNSBlock listing application
29th Apr 20107:00 amRNSNew positive data to be presented at US conference
1st Apr 20109:58 amRNSHolding in Company
31st Mar 20104:35 pmRNSHolding(s) in Company
22nd Mar 201010:44 amRNSReNeuron cited as UK regenerative medicine leader
18th Mar 20107:00 amRNSReNeuron signs further manufacturing contracts
15th Mar 20102:44 pmRNSSecond Closing of the Placing
12th Mar 201012:18 pmRNSResult of General Meeting
3rd Mar 20107:00 amRNSReNeuron presents pre-clinical efficacy data
22nd Feb 20107:00 amRNSReNeuron Announces Fundraising
18th Feb 20107:00 amRNSRetinal Stem Cell Research Grant
10th Feb 20107:00 amRNSFinal Approval Received To Commence Stroke Trial
8th Feb 201012:55 pmRNSIssue of Ordinary Shares
1st Feb 20107:00 amRNSClinical Advisory Board appointments
28th Jan 20107:00 amRNSRegulatory update
27th Jan 201011:42 amRNSReNeuron welcomes "Life Sciences 2010" report
1st Dec 20097:00 amRNSIssue of Ordinary Shares
27th Nov 20097:00 amRNSTwo grants awarded by regenerative funding program
26th Nov 20097:02 amRNS?5 million equity funding facility secured
26th Nov 20097:00 amRNSHalf Yearly Report
23rd Nov 20097:00 amRNSNotice of Results
16th Nov 20097:00 amRNSPositive data presented at leading US conference
22nd Oct 20091:49 pmRNSReNeuron to present at Royal Society of Medicine
2nd Oct 20097:00 amRNSPublication of new research using ReNcell
17th Sep 200910:47 amRNSResult of AGM
17th Sep 20097:00 amRNSAGM Statement
14th Sep 20097:02 amRNSTrading Platform
14th Sep 20097:00 amRNSChange of Adviser
10th Sep 20097:00 amRNSAngel and Reneuron announce contract
10th Sep 20097:00 amRNSRe Agreement
9th Sep 20095:00 pmRNSHolding(s) in Company
12th Aug 20097:00 amRNSDirector/PDMR Shareholding
11th Aug 20097:00 amRNSPublication of papers in peer-reviewed journals
10th Aug 20099:28 amRNSPublication of pre-clinical data
31st Jul 200911:21 amRNS2008/09 Annual Report and Accounts
30th Jul 200910:05 amRNSRegulatory Update
14th Jul 20093:48 pmRNSLaunch of "Life Sciences Blueprint"
8th Jul 20099:33 amRNSPublication of data on lead CTX stem cell line
30th Jun 20097:00 amRNSFinal Results
29th Jun 20093:44 pmRNSHolding(s) in Company
24th Jun 200910:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.